Oncostellae

Pipeline

Pipeline

OST-122     (IBD, fibrosis, CRC)

Oral, GI-restricted JAK3/TYK2-ARK5 inhibitor

DISCOVERY 100%
OPTIMIZATION 100%
PRECLINICAL 100%
PHASE I 18%

OST-476    (Autoimmune diseases)

Oral, systemic JAK3/TYK2-MLK3 inhibitor

DISCOVERY 100%
OPTIMIZATION
PRECLINICAL 0%
PHASE I 0%

OST-428    (CRPC, Immune Activation)

Oral GR antagonist

DISCOVERY 100%
OPTIMIZATION 80%
PRECLINICAL 0%
PHASE I 0%